(CercleFinance.com) – Nicox announced on Monday that it had 9.1 million euros in cash as of March 31, compared to 11.9 million at the end of 2023, which allows it to ensure its financing at least until November 2024.
The ophthalmology specialist says it is currently examining additional financing options, including discussions on business development that could provide non-dilutive capital.
At the same time, the biopharmaceutical company is working on planning a fundraising on the stock markets.
Nicox’s net loss for the whole of 2023 was reduced to 20.9 million euros, compared with a shortfall of 31.3 million for the whole of 2022.
Its turnover for the financial year increased to 6.9 million, mainly derived from royalties for concessions of its patents, compared to 5.5 million euros in 2022.
In the first quarter, its turnover reached 4.4 million euros, compared to 1.3 million euros for the first quarter of 2023.
As of March 31, its financial debt amounted to 20.6 million euros, including 19.4 million euros of outstanding debt with a BlackRock subsidiary and 1.2 million loans guaranteed by the State. following the Covid pandemic.
On the Paris Stock Exchange, Nicox shares lost 0.4%, bringing their decline since the start of the year to more than 14%.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Are you following this action?
Receive all the information on NICOX in real time: